Literature DB >> 10398165

Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver.

C J de Boer1, J H van Krieken, C M Janssen-van Rhijn, S V Litvinov.   

Abstract

Ep-CAM is a homophilic, Ca2+-independent cell-cell adhesion molecule that is expressed in many human epithelial tissues. Its increased expression is closely associated with active cell proliferation. Furthermore, in epithelial cell types that in adults lack Ep-CAM (i. e. squamous epithelia), up-regulation of Ep-CAM coincides with the early stages of neoplastic change. This study has analysed the expression of Ep-CAM in liver, in the hepatocytes and cells of the biliary duct system, in relation to proliferative diseases and carcinogenesis. Adult hepatocytes are Ep-CAM negative, with only bile duct epithelium being positive in the liver tissue. However, in the 8-week embryonic liver, the majority of hepatocytes express Ep-CAM. During regeneration and repair of liver tissues associated with focal nodular hyperplasia and (biliary) cirrhosis, activation of Ep-CAM expression was observed, with high expression levels in so-called 'ductular proliferations'-regenerating stem cells. During precursor cell differentiation into mature hepatocytes, several intermediate morphological stages could be observed, all Ep-CAM positive, including cells morphologically close to mature hepatocytes. Full maturation of the precursor resulted in the disappearance of Ep-CAM expression. The results suggest that expression of Ep-CAM is a prerequisite of the proliferative phenotype during differentiation of hepatocyte precursors. In liver neoplasia, Ep-CAM was expressed in almost all cholangiocarcinomas (10/11), whereas the majority of hepatocellular carcinomas (8/10) were negative, suggesting that malignant proliferation of hepatocellular carcinoma cells is not related to expression of Ep-CAM and that hepatocellular carcinoma originates from a highly differentiated precursor. The results indicate that Ep-CAM can be used as an additional immunohistochemical marker to distinguish cholangiocarcinoma from hepatocellular carcinoma due to the differential expression of Ep-CAM in these tumours. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398165     DOI: 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  76 in total

1.  Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.

Authors:  Leo L Studach; Stephan Menne; Stefano Cairo; Marie Annick Buendia; Ronald L Hullinger; Lydie Lefrançois; Philippe Merle; Ourania M Andrisani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 2.  EpCAM and its potential role in tumor-initiating cells.

Authors:  Sannia Imrich; Matthias Hachmeister; Olivier Gires
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

Review 3.  Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Authors:  Pooja Chaudhari; Lipeng Tian; Abhijeet Deshmukh; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

4.  Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules.

Authors:  Qin Zhang; Chuan-Shan Zhang; Qi Xin; Zhe Ma; Gui-Qiu Liu; Bing-Bing Liu; Feng-Mei Wang; Ying-Tang Gao; Zhi Du
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase.

Authors:  Manon J Winter; Vincenzo Cirulli; Inge H Briaire-de Bruijn; Sergey V Litvinov
Journal:  Mol Cell Biochem       Date:  2007-02-14       Impact factor: 3.396

Review 6.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

7.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Authors:  Colin M Court; Shuang Hou; Paul Winograd; Nicholas H Segel; Qingyu Wilda Li; Yazhen Zhu; Saeed Sadeghi; Richard S Finn; Ekambaram Ganapathy; Min Song; Samuel W French; Bita V Naini; Shonan Sho; Fady M Kaldas; Ronald W Busuttil; James S Tomlinson; Hsian-Rong Tseng; Vatche G Agopian
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

8.  Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay.

Authors:  Yu Zhang; Xiaofeng Zhang; Jinling Zhang; Bin Sun; Lulu Zheng; Jun Li; Sixiu Liu; Guodong Sui; Zhengfeng Yin
Journal:  Cancer Biol Ther       Date:  2016-09-23       Impact factor: 4.742

9.  Identification of a candidate stem cell in human gallbladder.

Authors:  Rohan Manohar; Yaming Li; Helene Fohrer; Lynda Guzik; Donna Beer Stolz; Uma R Chandran; William A LaFramboise; Eric Lagasse
Journal:  Stem Cell Res       Date:  2015-02-07       Impact factor: 2.020

Review 10.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.